Literature DB >> 33967447

Anticoagulation in ECMO patients: an overview.

Gaurav Kumar1, Ashish Maskey2.   

Abstract

Extracorporeal membrane oxygenation (ECMO) is a form of cardiorespiratory support, and is being increasingly used to support refractory heart and respiratory failure. It involves draining blood from the vascular system, which is then circulated outside the body by a mechanical pump and then later reinfused back into the circulation. The blood that is circulated outside the body comes in contact with a large surface area of non-endothelial biosurface. This exposure leads to a pro-thrombotic state, and hence anticoagulation is required. Unfractionated heparin is the most commonly used anticoagulation in most ECMO centers, but it does require close monitoring. Despite the advances made, hemostasis remains a challenge for physicians who manage patients on ECMO. © Indian Association of Cardiovascular-Thoracic Surgeons 2021.

Entities:  

Keywords:  Anticoagulation; Extracorporeal life support; Extracorporeal membrane oxygenation

Year:  2021        PMID: 33967447      PMCID: PMC8062644          DOI: 10.1007/s12055-021-01176-3

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  57 in total

1.  Guidelines on the use and monitoring of heparin.

Authors:  T Baglin; T W Barrowcliffe; A Cohen; M Greaves
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

2.  Activated clotting time (ACT).

Authors:  Stephen Horton; Simon Augustin
Journal:  Methods Mol Biol       Date:  2013

Review 3.  Complement-coagulation crosstalk on cellular and artificial surfaces.

Authors:  Rebecca Wiegner; Shinjini Chakraborty; Markus Huber-Lang
Journal:  Immunobiology       Date:  2016-06-19       Impact factor: 3.144

Review 4.  Platelet Physiology.

Authors:  Thomas Gremmel; Andrew L Frelinger; Alan D Michelson
Journal:  Semin Thromb Hemost       Date:  2016-02-29       Impact factor: 4.180

5.  Bivalirudin Dosing Requirements in Adult Patients on Extracorporeal Life Support With or Without Continuous Renal Replacement Therapy.

Authors:  Elizabeth A Walker; A Joshua Roberts; Erin L Louie; William E Dager
Journal:  ASAIO J       Date:  2019-02       Impact factor: 2.872

6.  Proteins, platelets, and blood coagulation at biomaterial interfaces.

Authors:  Li-Chong Xu; James W Bauer; Christopher A Siedlecki
Journal:  Colloids Surf B Biointerfaces       Date:  2014-09-28       Impact factor: 5.268

Review 7.  Function of von Willebrand factor in haemostasis and thrombosis.

Authors:  A J Reininger
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

Review 8.  Treating heparin resistance with antithrombin or fresh frozen plasma.

Authors:  Bruce D Spiess
Journal:  Ann Thorac Surg       Date:  2008-06       Impact factor: 4.330

9.  Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.

Authors:  Richard Robson; Harvey White; Philip Aylward; Christopher Frampton
Journal:  Clin Pharmacol Ther       Date:  2002-06       Impact factor: 6.875

10.  Association of bleeding and thrombosis with outcome in extracorporeal life support.

Authors:  Heidi J Dalton; Pamela Garcia-Filion; Richard Holubkov; Frank W Moler; Thomas Shanley; Sabrina Heidemann; Kathleen Meert; Robert A Berg; John Berger; Joseph Carcillo; Christopher Newth; Richard Harrison; Allan Doctor; Peter Rycus; J Michael Dean; Tammara Jenkins; Carol Nicholson
Journal:  Pediatr Crit Care Med       Date:  2015-02       Impact factor: 3.624

View more
  1 in total

1.  The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation.

Authors:  Jae Ha Lee; Jin Han Park; Ji Hoon Jang; Se Hun Kim; Sung Yong Hong; Woon Heo; Dong-Hwan Lee; Hye Sook Choi; Ki Hoon Kim; Hang-Jea Jang
Journal:  Acute Crit Care       Date:  2022-04-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.